Role of MELK in glioblastomas

MELK 在胶质母细胞瘤中的作用

基本信息

项目摘要

DESCRIPTION (provided by applicant): Malignant gliomablastomas (GBMs) are the most common and fatal brain tumors with no definitive treatment available to date. Recent studies identified a small population of cells (1-10%) with stem- like features in glioblastomas. We identified the Maternal Embryonic Leucine zipper Kinase (MELK) as a marker for normal hematopoietic and neural progenitors. In addition, we and others have implicated MELK in tumor growth and proposed it as a therapeutic target for GBMs. Despite the solid body of in vitro data suggesting that MELK is selectively upregulated in GBM compared to normal brain, no in vivo evidence is available to date establishing MELK expression as a marker for tumor-initiating cells or documenting its ubiquitous expression throughout the tumor. In this proposal we will investigate whether MELK plays role in GBM and whether MELK expression enriches for tumor-initiating cells in vivo. We will take advantage of MELK-GFP promoter-reporter to prospectively isolate MELK-high/-low cells by FACS and transplant them at limiting dilutions in recipient brain to determine their tumor-initiating capacity (Aim1). We will determine whether MELK catalytic function is required for tumorigenesis in vivo. (Aim 2). We will investigate whether the germ line ablation of MELK catalytic function (3MELK mice) eliminates/reduces experimental glioblastomas in the Ink4/Arf-null,/EGFRvIII mouse model. It is possible that various mechanisms compensate for the lack of MELK during development. To address this issue we will use a transplantation approach to determine whether knocking down MELK expression using shRNA will inhibit GBM formation in vivo. Finally, we will test small molecule inhibitors of MELK in vitro using primary human GBMs. We will validate 6 existing lead MELK inhibitors in primary human GBM lines and optimize the most potent MELK inhibitors using combinatorial/medicinal chemistry. The expression analysis of primary tumors identified hundreds of gene candidates. The critical remaining question is: which genes represent promising therapeutic targets? Validation of a particular protein to be a relevant and realistic target for treatment is literally a life-and-death decision. Given the success of Gleevec, Iressa, Tarceva, and other small molecule inhibitors of kinase catalytic activity, MELK as kinase presents a formidable opportunity for drug development. Although we and others previously proposed MELK as a unique drug target for GBM treatment, no in vivo validation has been demonstrated to date. The significance of this proposal is in validating MELK, in particular its catalytic activity, as a drug target for GBMs both in animal models using a genetic approach and in primary human GBM lines in culture using candidate small molecule inhibitors of MELK. PUBLIC HEALTH RELEVANCE: Malignant gliomablastomas (GBMs) are the most common and fatal brain tumors with no definitive treatment available to date. The expression analysis of primary tumors identified hundreds of gene candidates. The critical remaining question is: which genes represent promising therapeutic targets? The goal of this proposal is to validating MELK as a drug target for GBMs both in animal models using a genetic approach and in primary human GBM lines in culture using candidate small molecule inhibitors of MELK.
描述(由申请人提供):恶性胶质瘤母细胞瘤(GBMs)是最常见和致命的脑肿瘤,迄今尚无明确的治疗方法。最近的研究发现,胶质母细胞瘤中有一小部分细胞(1-10%)具有干细胞样特征。我们鉴定了母胚亮氨酸拉链激酶(MELK)作为正常造血和神经祖细胞的标记物。此外,我们和其他人认为MELK与肿瘤生长有关,并提出它是GBMs的治疗靶点。尽管大量的体外实验数据表明,与正常大脑相比,GBM中MELK的表达有选择性上调,但到目前为止,还没有体内证据表明MELK表达是肿瘤启动细胞的标志,也没有证据表明其在整个肿瘤中的普遍表达。在本课题中,我们将研究MELK是否在GBM中发挥作用,以及MELK是否在体内肿瘤启动细胞中表达丰富。我们将利用MELK-GFP启动子报告子,通过FACS前瞻性地分离melk -高/低细胞,并将其以有限的稀释度移植到受体脑中,以确定其肿瘤启动能力(Aim1)。我们将确定MELK的催化功能是否需要体内肿瘤发生。(目标2)。我们将在Ink4/Arf-null,/EGFRvIII小鼠模型中研究种系消融MELK催化功能(3MELK小鼠)是否消除/减少实验性胶质母细胞瘤。有可能在开发过程中有各种机制弥补MELK的不足。为了解决这个问题,我们将使用移植方法来确定使用shRNA抑制MELK表达是否会抑制体内GBM的形成。最后,我们将在体外用原代人GBMs测试MELK的小分子抑制剂。我们将在原发性人GBM细胞系中验证6种现有的MELK先导抑制剂,并使用组合/药物化学优化最有效的MELK抑制剂。原发肿瘤的表达分析确定了数百个候选基因。剩下的关键问题是:哪些基因代表了有希望的治疗靶点?验证一个特定的蛋白质是一个相关的和现实的治疗目标是一个生死攸关的决定。鉴于格列卫、易瑞沙、特罗凯等激酶催化活性小分子抑制剂的成功,MELK作为激酶为药物开发提供了巨大的机会。虽然我们和其他人之前提出MELK作为GBM治疗的独特药物靶点,但迄今为止还没有得到体内验证。该建议的意义在于验证MELK,特别是其催化活性,作为GBMs的药物靶点,在动物模型中使用遗传方法,在培养的初级人类GBM系中使用候选的MELK小分子抑制剂。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ALEXEY V TERSKIKH其他文献

ALEXEY V TERSKIKH的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ALEXEY V TERSKIKH', 18)}}的其他基金

Testing the utility of miBioAge as a personalized aging biomarker
测试 miBioAge 作为个性化衰老生物标志物的实用性
  • 批准号:
    10728233
  • 财政年份:
    2023
  • 资助金额:
    $ 43.09万
  • 项目类别:
Novel Strategy to Quantitate Delayed Aging by Caloric Restriction
通过热量限制来量化延迟衰老的新策略
  • 批准号:
    10594352
  • 财政年份:
    2022
  • 资助金额:
    $ 43.09万
  • 项目类别:
Novel Strategy to Quantitate Delayed Aging by Caloric Restriction
通过热量限制来量化延迟衰老的新策略
  • 批准号:
    10355362
  • 财政年份:
    2022
  • 资助金额:
    $ 43.09万
  • 项目类别:
Novel Strategy to Quantitate Delayed Aging by Caloric Restriction
通过热量限制来量化延迟衰老的新策略
  • 批准号:
    10570275
  • 财政年份:
    2022
  • 资助金额:
    $ 43.09万
  • 项目类别:
Role of Epigenetically Active Environmental Compounds in Neurodevelopmental Disorders
表观遗传活性环境化合物在神经发育障碍中的作用
  • 批准号:
    10219009
  • 财政年份:
    2021
  • 资助金额:
    $ 43.09万
  • 项目类别:
Role of Epigenetically Active Environmental Compounds in Neurodevelopmental Disorders
表观遗传活性环境化合物在神经发育障碍中的作用
  • 批准号:
    10395566
  • 财政年份:
    2021
  • 资助金额:
    $ 43.09万
  • 项目类别:
Phenotypic Screening for Longevity Interventions Using Single-cell Epigenetic Signatures
使用单细胞表观遗传特征进行长寿干预的表型筛选
  • 批准号:
    10225468
  • 财政年份:
    2020
  • 资助金额:
    $ 43.09万
  • 项目类别:
Role of Epigenetically Active Environmental Compounds in Neurodevelopmental Disorders
表观遗传活性环境化合物在神经发育障碍中的作用
  • 批准号:
    10271253
  • 财政年份:
    2020
  • 资助金额:
    $ 43.09万
  • 项目类别:
Role of Epigenetically Active Environmental Compounds in Neurodevelopmental Disorders
表观遗传活性环境化合物在神经发育障碍中的作用
  • 批准号:
    9979666
  • 财政年份:
    2020
  • 资助金额:
    $ 43.09万
  • 项目类别:
Phenotypic Screening for Longevity Interventions Using Single-cell Epigenetic Signatures
使用单细胞表观遗传特征进行长寿干预的表型筛选
  • 批准号:
    10043841
  • 财政年份:
    2020
  • 资助金额:
    $ 43.09万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 43.09万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 43.09万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.09万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.09万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 43.09万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.09万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 43.09万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 43.09万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 43.09万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.09万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了